Fig. 5: Evaluation of the safety of IMRC transfusion.

a t-SNE projection of single cells and their pluripotency gene expression amongst IMRCs. b In vivo imaging of the far red fluorescence in mice after injection of DiR-labeled IMRCs. c Quantification of the DiR fluorescent radiance in the whole body over time. d Immunofluorescence staining of lung sections for the endothelial marker CD31 and the alveolar epithelial marker SPC, 21 days after injecting GFP-labeled IMRCs. Scale bar, 100 µm. e Soft agar colony formation assay for the tumorigenic potential of IMRCs, relative to PANC-1 cancer cells and hESCs. Scale bar, 100 µm. f Single nucleotide variants (SNVs) and insertions/deletions (InDels) in the non-repeat regions of the IMRCs genome, relative to hESCs. g Blood biochemistry results of cynomolgus monkeys (Macaca fascicularis) injected with a low (2.6 × 10⁶), medium (2.6 × 10⁷) or high (1 × 10⁸) dose of IMRCs after 6 months. AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, CK creatine phosphokinase, GGT glutamyltransferase, LDH lactate dehydrogenase, TBIL total bilirubin, BUN urea nitrogen, CRE creatinine, GLU glucose, CHO total cholesterol, TG triglyceride, TP total protein, ALB albumin, A/G albumin/globulin. h Urinalysis results of cynomolgus monkeys (Macaca fascicularis) injected with a low (2.6 × 10⁶), medium (2.6 × 10⁷) or high (1 × 10⁸) dose of IMRCs after 6 months. PRO urine protein, BIL urine bilirubin, URO urinary gallbladder, pH acid degree value, SG specific gravity, ERY erythrocyte, KET ketone, NIT nitrite. *P < 0.05, **P < 0.01, ***P < 0.001; data are represented as the mean ± SEM.